Hale, D A <br/><br/>
Use of CTLA4-Ig in combination with conventional immunosuppressive agents to prolong allograft survival.  [electronic resource] 

 -  Transplantation  Sep 1997 
 - 897-900 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0041-1337 
<br/><br/><label>Standard No.: </label>10.1097/00007890-199709270-00018  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Abatacept<br/>Animals<br/>Antigens, CD<br/>Antigens, Differentiation--therapeutic use<br/>Antilymphocyte Serum--therapeutic use<br/>Bone Marrow Transplantation--immunology<br/>CTLA-4 Antigen<br/>Cyclosporine--therapeutic use<br/>Drug Therapy, Combination<br/>Graft Survival--drug effects<br/>Histocompatibility Testing<br/>Immunization, Passive<br/>Immunoconjugates<br/>Immunosuppression Therapy--methods<br/>Immunosuppressive Agents--therapeutic use<br/>Mice<br/>Mice, Inbred AKR<br/>Mice, Inbred C3H<br/>Mice, Inbred C57BL<br/>Polyenes--therapeutic use<br/>Sirolimus<br/>Skin Transplantation--immunology<br/>Transplantation, Homologous